IRLAB Therapeutics Pašu kapitāls 2024

Ko dara IRLAB Therapeutics?

IRLAB Therapeutics AB was founded in Stockholm, Sweden in 2012 and is a biopharmaceutical company specializing in the development of drugs for neurodegenerative diseases. The company has an innovative business model based on the discovery, development, and commercialization of drug candidates for various diseases. The company specializes in developing new and effective treatment options for neurodegenerative diseases. IRLAB Therapeutics AB has an extensive network of partners, including scientific institutions, universities, and clinical trial centers. With this network, the company ensures that all research and development activities are conducted using the latest scientific and technological advancements. The company operates in two segments: research and development and commercialization. In the research and development segment, the company focuses on identifying and developing drugs for neurodegenerative diseases such as Parkinson's and Alzheimer's. The company works on a pipeline of drug candidates in various stages of development, using advanced technologies such as in-silico screening and in-vivo testing to identify and develop new drug candidates. The commercialization segment of the company mainly deals with the distribution of already approved drugs. The company specializes in bringing these medications to market in its target regions. The company is particularly focused on the drugs Systebol and IRL752. Systebol is a medication for the treatment of cold-like symptoms in pregnant women and is already approved in some countries around the world. IRL752 is a substance for the treatment of psychiatric disorders and is also marketed by IRLAB Therapeutics. The main product of IRLAB Therapeutics AB is currently P21, a drug candidate for the treatment of Parkinson's disease. This drug candidate is in phase II of clinical trials and has received Orphan Drug designation from both the FDA and EMA. The company regularly reports on the progress of the clinical trials and announces ongoing news about the results. IRLAB Therapeutics AB has a clear vision and mission based on providing innovative solutions for patients with neurodegenerative diseases. The company aims to improve the lives of millions of people worldwide through the development of new and effective medical solutions. The company relies on collaboration with global and regional partners and invests in advanced technologies to establish itself as an innovative and reliable partner in the pharmaceutical industry. IRLAB Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.